Meeting
2024 ASCO Genitourinary Cancers Symposium
Coformulation of pembrolizumab and vibostolimab in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort G.
Authors
Peter C.C. Fong
Auckland City Hospital and University of Auckland, Auckland, New Zealand
Peter C.C. Fong , Mariusz Kwiatkowski , Alessandra Mosca , Begona Perez Valderrama , Yi-Hsiu Huang , Ahmed H. Zedan , Kamil Kuc , Pawel Wiechno , Brigitte Laguerre , Enrique Gonzalez-Billalabeitia , Mikhail Osipov , Didem Sener Dede , Jeffrey Goh , Gedske Daugaard , Pengfei Zhu , Kentaro Imai , yingjie liu , Jose Angel Arranz Arija
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02861573
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 149)
DOI
10.1200/JCO.2024.42.4_suppl.149
Abstract #
149
Poster Bd #
F20
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.
First Author: Srikala S. Sridhar
Poster
2020 ASCO Virtual Scientific Program
Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.
First Author: Henry Jacob Conter
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 1b/2 study of pembrolizumab (pembro) plus platinum/etoposide and platinum/etoposide for neuroendocrine metastatic prostate cancer (NEPC): KEYNOTE-365 cohort I.
First Author: Evan Y. Yu
Poster
2022 ASCO Genitourinary Cancers Symposium
KEYNOTE-365 cohorts E and F: Phase 1b/2 study of pembrolizumab + lenvatinib combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).
First Author: Gero Kramer